可降解支架治疗食管癌根治性治疗后难治性良性食管狭窄的前瞻性试验
这项前瞻性试验纳入18例食管癌根治性治疗(食管切除术、内镜黏膜下剥离术或放化疗)后难治性良性食管狭窄患者,置入可降解支架。12周时66.7%患者吞咽困难评分改善,24周时仅16.7%维持改善,中位无吞咽困难生存期14.1周,1例发生食管支气管瘘。
要点
- 可降解支架置入后12周吞咽困难评分改善比例为66.7%(90% CI,44.6%-84.4%)。
- 24周时仅16.7%患者维持吞咽困难评分改善(95% CI,3.6%-41.4%)。
- 中位无吞咽困难生存期为14.1周(95% CI,13.0-19.0),1例出现食管支气管瘘。
核心结论
- 可降解支架对食管癌治疗后难治性良性食管狭窄有效且可耐受,但长期疗效有限,尤其在内镜黏膜下剥离术或放化疗后。
研究设计与样本
- 前瞻性试验纳入18例吞咽困难评分≥2分且标准内镜无法通过的难治性良性食管狭窄患者(男15例、女3例;中位年龄72岁,范围53-80岁)。
- 主要终点为支架置入后12周吞咽困难评分改善比例,次要终点为24周改善比例、无吞咽困难生存期及不良事件。
主要发现
- 12周时12例患者吞咽困难评分改善,改善比例为66.7%(90% CI,44.6%-84.4%)。
- 12周时食管切除术后8/11例(72.7%)、内镜黏膜下剥离术后4/6例(66.7%)、放化疗后3/4例(75%)吞咽困难评分改善。
- 24周时3例食管切除术后患者维持吞咽困难评分改善,改善比例为16.7%(95% CI,3.6%-41.4%)。
- 中位无吞咽困难生存期为14.1周(95% CI,13.0-19.0)。
- 1例接受内镜黏膜下剥离术和放化疗的患者在支架置入3个月后发生食管支气管瘘。
局限性
- 长期疗效有限,尤其在内镜黏膜下剥离术或放化疗后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Biodegradable stents are reportedly effective for refractory benign esophageal strictures; however, little is known about their use in patients with refractory stricture after endoscopic submucosal dissection (ESD) or chemoradiotherapy (CRT) for esophageal cancer. This study aimed to evaluate the effectiveness of biodegradable stents for these patients. METHODS: Patients with refractory benign esophageal stricture with a dysphagia score (DS) of 2 or worse and for whom the passage of a standard size endoscope was not possible were eligible. The primary endpoint was the proportion of those who improved their DSs (% DS improved) at 12 weeks after stent placement, and the secondary endpoints were the proportion of those who improved their DSs at 24 weeks, dysphagia-free survival (DFS), and adverse events. RESULTS: Eighteen patients (men:women, 15:3; median age, 72 years; range, 53-80) were enrolled. Twelve patients improved their DS at 12 weeks (% DS improved, 66.7%; 90% CI, 44.6%-84.4%). Also, 8 of 11 patients (72.7%) after esophagectomy, 4 of 6 patients (66.7%) after ESD, and 3 of 4 patients (75%) after CRT improved at 12 weeks. Three patients who were treated with esophagectomy maintained their DS improvement at 24 weeks (% DS improved, 16.7%; 95% CI, 3.6%-41.4%). The median DFS was 14.1 weeks (95% CI, 13.0-19.0). One patient who had ESD and CRT developed an esophagobronchial fistula 3 months after stent placement. CONCLUSIONS: Biodegradable stents are effective and tolerable for refractory benign esophageal strictures after treatment for esophageal cancer; however, long-term efficacy was limited, especially after ESD or CRT. (Clinical trial registration number: UMIN000008054.).
引用
- Yano T, Yoda Y, Nomura S, et al. Prospective trial of biodegradable stents for refractory benign esophageal strictures after curative treatment of esophageal cancer. Gastrointest Endosc. 2017. PMID: 28137598. doi:10.1016/j.gie.2017.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。